AVP and metabolic syndrome: We previously showed in population-based studies that high copeptin, a stable plasma marker of vasopressin (VP), is independently associated with all components of the metabolic syndrome [7–9], increased risk of developing type 2 diabetes and overweight [7, 8] as well as increased risk of heart disease and cardiovascular mortality [10–12].